Drug Shortage Report for TEVA-EMTRICITABINE/TENOFOVIR
Report ID | 159201 |
Drug Identification Number | 02399059 |
Brand name | TEVA-EMTRICITABINE/TENOFOVIR |
Common or Proper name | EMTRICITABINE/TENOFOVIR 200/300MG |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE |
Strength(s) | 300MG 200MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30 |
ATC code | J05AR |
ATC description | DIRECT ACTING ANTIVIRALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-04-20 |
Estimated end date | 2023-06-10 |
Actual end date | 2023-06-20 |
Shortage status | Resolved |
Updated date | 2023-06-21 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v37 | 2023-06-21 | English | Compare |
v36 | 2023-06-20 | French | Compare |
v35 | 2023-06-20 | English | Compare |
v34 | 2023-06-09 | French | Compare |
v33 | 2023-06-09 | English | Compare |
v32 | 2023-04-27 | French | Compare |
v31 | 2023-04-27 | English | Compare |
v30 | 2023-02-09 | French | Compare |
v29 | 2023-02-09 | English | Compare |
v28 | 2023-02-02 | French | Compare |
v27 | 2023-02-02 | English | Compare |
v26 | 2023-01-12 | French | Compare |
v25 | 2023-01-12 | English | Compare |
v24 | 2022-12-22 | French | Compare |
v23 | 2022-12-22 | English | Compare |
v22 | 2022-12-15 | French | Compare |
v21 | 2022-12-15 | English | Compare |
v20 | 2022-12-01 | French | Compare |
v19 | 2022-12-01 | English | Compare |
v18 | 2022-12-01 | French | Compare |